Table 1.
Baseline characteristics of patients with AF and COPD taking BBs.
| Patient Baseline Characteristics | ||||
|---|---|---|---|---|
| Characteristic | N | Non-Cardioselective BB, N = 48 | Cardioselective BB, N = 71 | p-Value a |
| Age, median (IQR b) | 117 | 77 (12) | 76 (11) | >0.9 |
| Gender, n/N (%) | 119 | <0.01 | ||
| Male | 37/48 (77%) | 36/71 (51%) | ||
| Female | 11/48 (23%) | 35/71 (49%) | ||
| BMI b, median (IQR b) | 116 | 28.1 (6.5) | 27.6 (6.7) | 0.8 |
| Smoking, n/N (%) | 116 | 36/47 (77%) | 47/69 (68%) | 0.3 |
| LVEF, n/N (%) | 117 | 0.5 | ||
| >40% | 31/48 (65%) | 49/69 (71%) | ||
| ≤40% | 17/48 (35%) | 20/69 (29%) | ||
| CAD, n/N (%) | 117 | 33/47 (70%) | 25/70 (36%) | <0.001 |
| Prior MI b, n/N (%) | 117 | 22/47 (47%) | 14/70 (20%) | <0.01 |
| AH b, n/N (%) | 117 | 42/48 (88%) | 60/69 (87%) | >0.9 |
| Diabetes Mellitus, n/N (%) | 119 | 26/48 (54%) | 22/71 (31%) | 0.011 |
| Dylipidemia, n/N (%) | 118 | 26/47 (55%) | 37/71 (52%) | 0.7 |
| CKD b, n/N (%) | 117 | 13/47 (28%) | 13/70 (19%) | 0.2 |
| Prior Stroke, n/N (%) | 117 | 15/48 (31%) | 10/69 (14%) | 0.03 |
| AF type, n/N (%) | 115 | 0.7 | ||
| Non-valvular | 5/48 (10.4%) | 4/71 (5.6%) | ||
| Valvular | 43/48 (89.6%) | 67/71 (94.4%) | ||
| OACs b, n/N (%) | 115 | 0.2 | ||
| no | 6/47 (13%) | 6/68 (8.8%) | ||
| VKA b | 19/47 (40%) | 19/68 (28%) | ||
| NOAC b | 22/47 (47%) | 43/68 (63%) | ||
| Anti-PLTs b, n/N (%) | 111 | 0.2 | ||
| No | 43/47 (91%) | 53/64 (83%) | ||
| Aspirin | 3/47 (6.4%) | 2/64 (3.1%) | ||
| Clopidogrel | 0/47 (0%) | 3/64 (4.7%) | ||
| Aspirin and clopidogrel | 1/47 (2.1%) | 6/64 (9.4%) | ||
| CHA2DS2_VASC,n/N (%) | 118 | 0.2 | ||
| Low risk | 1/47 (2.1%) | 6/71 (8.5%) | ||
| High risk | 46/47 (98%) | 65/71 (92%) | ||
| Corticosteroids, n/N (%) | 114 | 0.6 | ||
| No | 27/46 (59%) | 38/68 (56%) | ||
| inhalative | 17/46 (37%) | 29/68 (43%) | ||
| per os | 2/46 (4.3%) | 1/68 (1.5%) | ||
| Inhalatives, n/N (%) | 114 | 0.5 | ||
| No | 22/46 (48%) | 34/68 (50%) | ||
| SABA | 2/46 (4.3%) | 3/68 (4.4%) | ||
| LABA | 20/46 (43%) | 31/68 (46%) | ||
| SABA and LABA | 2/46 (4.3%) | 0/68 (0%) | ||
a Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence; Fisher’s exact test. b BMI = body mass index, IQR = interquartile range, MI = myocardial infarction, AH = arterial hypertension, CKD = chronic kidney disease, OAC = oral anticoagulant, VKA = vitamin K antagonist, NOAC = new oral anticoagulant, and PLTs = platelets. p-values marked in bold indicate statistically significant tests (p < 0.05).